A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Isatuximab in Patients With Multiple Myeloma
Public ClinicalTrials.gov record NCT02514668. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-label, Dose-escalation and Multi-center Study to Evaluate the Safety, Pharmacokinetics and Efficacy of SAR650984 (Isatuximab) in Patients With Relapsed/Refractory Multiple Myeloma
Study identification
- NCT ID
- NCT02514668
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Sanofi
- Industry
- Enrollment
- 55 participants
Conditions and interventions
Conditions
Interventions
- Isatuximab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 31, 2015
- Primary completion
- Dec 1, 2021
- Completion
- Dec 1, 2021
- Last update posted
- Apr 24, 2022
2015 – 2021
United States locations
- U.S. sites
- 10
- U.S. states
- 10
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Investigational Site Number 840003 | Scottsdale | Arizona | 85054 | — |
| Investigational Site Number 840004 | San Francisco | California | 94117 | — |
| Investigational Site Number 840011 | Detroit | Michigan | 48201 | — |
| Investigational Site Number 840015 | St Louis | Missouri | 63110 | — |
| Investigational Site Number 840005 | Hackensack | New Jersey | 07601 | — |
| Investigational Site Number 840010 | Durham | North Carolina | 27707 | — |
| Investigational Site Number 840013 | Canton | Ohio | 44718 | — |
| Investigational Site Number 840001 | Nashville | Tennessee | 37232 | — |
| Investigational Site Number 840002 | Salt Lake City | Utah | 84112-5550 | — |
| Investigational Site Number 840006 | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 8 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02514668, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 24, 2022 · Synced Jul 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02514668 live on ClinicalTrials.gov.